Literature DB >> 6584184

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

J E Sokal, E B Cox, M Baccarani, S Tura, G A Gomez, J E Robertson, C Y Tso, T J Braun, B D Clarkson, F Cervantes.   

Abstract

The prognostic significance of disease features recorded at the time of diagnosis was examined among 813 patients with Philadelphia chromosome-positive, nonblastic chronic granulocytic leukemia (CGL) collected from six European and American series. The survival pattern for this population was typical of "good-risk" patients, and median survival was 47 mo. There were multiple interrelationships among different disease features, which led to highly significant correlations with survival for some that had no primary prognostic significance, such as hematocrit. Multivariable regression analysis indicated that spleen size and the percentage of circulating blasts were the most important prognostic indicators. These features, and age, behaved as continuous variables with progressively unfavorable import at higher values. The platelet count did not influence survival significantly at values below 700 X 10(9)/liter but was increasingly unfavorable above this level. Basophils plus eosinophils over 15%, more than 5% marrow blasts, and karyotypic abnormalities in addition to the Ph1 were also significant unfavorable signs. The Cox model, generated with four variables representing percent blasts, spleen size, platelet count, and age, provided a useful representation of risk status in this population, with good fit between predicted and observed survival over more than a twofold survival range. A hazard function derived from half of the patient population successfully segregated the remainder into three groups with significantly different survival patterns. We conclude that it should be possible to identify a lower risk group of patients with a 2-yr survival of 90%, subsequent risk averaging somewhat less than 20%/yr and median survival of 5 yr, an intermediate group, and a high-risk group with a 2-yr survival of 65%, followed by a death rate of about 35%/yr and median survival of 2.5 yr.

Entities:  

Mesh:

Year:  1984        PMID: 6584184

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  217 in total

1.  Prognostic implications of bone marrow features in chronic myelogenous leukaemia.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

2.  EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.

Authors:  Elias Jabbour; Jorge Cortes; Aziz Nazha; Susan O'Brien; Alfonso Quintas-Cardama; Sherry Pierce; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

Review 3.  Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value?

Authors:  Maxim Norkin; Charles A Schiffer
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

4.  Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Authors:  Mohamed El Missiry; Shady Adnan Awad; Hanna L Rajala; Ahmed Al-Samadi; Marja Ekblom; Berit Markevän; Ingbritt Åstrand-Grundström; Maren Wold; Ellen Rabben Svedahl; Birgitte Ravn Juhl; Ole Weis Bjerrum; Inger Haulin; Kimmo Porkka; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Satu Mustjoki
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

5.  Fluorescent in situ hybridization analysis of Philadelphia chromosome-negative chronic myeloid leukemia with the bcr/abl fusion gene.

Authors:  Fumihiko Monma; Kazuhiro Nishii; Shunji Yamamori; Noboru Hosokai; Takahiro Nakazaki; Felipe Lorenzo; Eiji Usui; Miho Sakakura; Hiroyuki Miyashita; Atsushi Fujieda; Kohshi Ohishi; Naoyuki Katayama; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

6.  Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia.

Authors:  Mustafa Pehlivan; Handan Haydaroglu Sahin; Sacide Pehlivan; Kursat Ozdilli; Leylagul Kaynar; Fatma Savran Oguz; Tugce Sever; Mehmet Yilmaz; Bulent Eser; Yeliz Duvarci Ogret; Cem Kis; Vahap Okan; Mustafa Cetin; Mahmut Carin
Journal:  Genet Test Mol Biomarkers       Date:  2014-05-12

Review 7.  Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.

Authors:  Akira Chiba; Takashi Toya; Hideaki Mizuno; Junji Tokushige; Fumihiko Nakamura; Kumi Nakazaki; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2018-08-04       Impact factor: 2.490

8.  Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.

Authors:  Richard E Clark; Jane F Apperley; Mhairi Copland; Silvia Cicconi
Journal:  Blood Adv       Date:  2021-02-23

Review 9.  Chronic myelogenous leukemia: elements of conventional chemotherapy and an overview of autografting in the treatment of the chronic phase.

Authors:  Vito Michele Lauta
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

10.  Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.

Authors:  Joseph Menzin; Kathleen Lang; Craig C Earle; Alastair Glendenning
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.